Phenylpropanolamine and the hemorrhagic stroke: A new search for the culprit
Mostafa Yakoot1★★ Corresponding author
- 1Green Clinic and Research Center, Green Street, Alexandria, Egypt.
CORRESPONDENCE
Mostafa Yakoot
Green Clinic and Research Center, Green Street, Alexandria, Egypt.
Volume 3, Issue 1 · pp. 4–6 · PUBLISHED 2012 · DOI: 10.4103/0976-500X.92491
ABSTRACT
Based primarily on the Final Report of the Hemorrhagic Stroke Project (HSP) released on May 2000,[3,4] the Food and Drug Administration (FDA) had concluded that there is an association between PPA and hemorrhagic stroke. In November 2000, the FDA formally recommended that PPA not be considered safe for the OTC use and asked the drug manufacturers to voluntarily discontinue marketing any products containing PPA.[5] As a consequence, in most countries, all of OTC and prescription diet aids, as well as cough and cold remedies containing PPA, were discontinued or reformulated with another decongestant. Ephedrine and pseudoephedrine were the mostly used substitutes as they share the pharmacological properties of PPA and are approximately similar in potency except that PPA causes less central nervous system stimulation
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Yakoot, M. (2012). Phenylpropanolamine and the hemorrhagic stroke: A new search for the culprit. Journal of Pharmacology and Pharmacotherapeutics, 3(1), 4–6. https://doi.org/10.4103/0976-500X.92491